In a report published Tuesday, Wedbush analyst Heather Behanna initiated coverage on Achaogen AKAO with a Neutral rating and $9.00 price target.
In the report, Wedbush noted, “We are initiating coverage with a NEUTRAL rating and $9 price target. Our price target is achieved by applying a 5x multiple on plazomicin peak US sales of ~$225M and a 15x multiple on plazomicin peak royalty revenue from EU sales. We apply a discount rate of 35% due to what we perceive as a high degree of clinical risk for the program.”
Achaogen closed on Tuesday at $10.41.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in